2 results
Approved WMOCompleted
The primary hypothesis of this study is that ibrutinib compared with temsirolimus significantly prolongs PFS in subjects with relapsed or refractory MCL who have received at least 1 prior rituximab-containing chemotherapy regimen.
Approved WMORecruiting
To investigate whether on demand dosing using population-based PK-models in VWD patients is reliable and feasible.